Overview Dividends

(TEVA) Teva Pharma Industries - Ratings and Ratios

Exchange: NYSE • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generics, Respiratory, CNS, Oncology, API

Pharmaceuticals
Market Cap in USD: 36,587m
IPO / Inception: 1990-03-26
Return 12m vs S&P 500: 20.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of TEVA over the last years for every Quarter: "2020-12": 0.68, "2021-03": 0.63, "2021-06": 0.59, "2021-09": 0.59, "2021-12": 0.77, "2022-03": 0.55, "2022-06": 0.68, "2022-09": 0.59, "2022-12": 0.71, "2023-03": 0.4, "2023-06": 0.56, "2023-09": 0.6, "2023-12": 1, "2024-03": 0.48, "2024-06": 0.61, "2024-09": -0.39, "2024-12": 0.71, "2025-03": 0.52, "2025-06": 0.66, "2025-09": 0.78,
EPS CAGR: 0.34%
EPS Trend: -14.2%
Last SUE: 0.28
Qual. Beats: 0

Revenue

Revenue of TEVA over the last years for every Quarter: 2020-12: 4453, 2021-03: 3982, 2021-06: 3910, 2021-09: 3887, 2021-12: 4100, 2022-03: 3661, 2022-06: 3786, 2022-09: 3595, 2022-12: 3883, 2023-03: 3661, 2023-06: 3878, 2023-09: 3850, 2023-12: 4457, 2024-03: 3819, 2024-06: 4164, 2024-09: 4331, 2024-12: 4229, 2025-03: 3891, 2025-06: 4176, 2025-09: 4480,
Rev. CAGR: 2.39%
Rev. Trend: 62.8%
Last SUE: 0.81
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 33.5%
Value at Risk 5%th 45.2%
Relative Tail Risk -17.99%
Reward TTM
Sharpe Ratio 0.87
Alpha 21.75
CAGR/Max DD 1.07
Character TTM
Hurst Exponent 0.262
Beta 0.946
Beta Downside 0.998
Drawdowns 3y
Max DD 43.70%
Mean DD 14.24%
Median DD 12.06%

Description: TEVA Teva Pharma Industries December 17, 2025

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global developer, manufacturer, and marketer of generic and specialty medicines, operating across the United States, Europe, Israel, and other markets. Its product portfolio spans oral solids, injectables, inhalation devices, transdermal patches, and combination products, with therapeutic focus on central nervous system, respiratory, and oncology indications. In addition to generic APIs and contract-manufacturing services, Teva commercializes branded therapies such as COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and TREANDA (chronic lymphocytic leukemia).

Key recent metrics: 2023 revenue was approximately $13.5 billion, while net debt remained high at roughly $30 billion, reflecting ongoing refinancing pressure. The company’s generic margin has been compressed by intensified price competition and FDA backlog, prompting a strategic shift toward higher-margin specialty and biosimilar launches. Macro-level drivers include an aging global population that sustains demand for CNS and respiratory treatments, and regulatory trends that favor faster biosimilar approvals, which can both create opportunities and heighten competitive risk for Teva.

For a deeper, data-driven valuation, see the TEVA profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (712.0m TTM) > 0 and > 6% of Revenue (6% = 1.01b TTM)
FCFTA 0.02 (>2.0%) and ΔFCFTA -0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 7.42% (prev -8.84%; Δ 16.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.04 (>3.0%) and CFO 1.41b > Net Income 712.0m (YES >=105%, WARN >=100%)
Net Debt (14.89b) to EBITDA (3.69b) ratio: 4.04 <= 3.0 (WARN <= 3.5)
Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.74% (target <= -2.0% for YES)
Gross Margin 50.09% (prev 49.84%; Δ 0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 41.11% (prev 40.16%; Δ 0.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 1.80 (EBITDA TTM 3.69b / Interest Expense TTM 1.49b) >= 6 (WARN >= 3)

Altman Z'' -1.06

(A) 0.03 = (Total Current Assets 12.74b - Total Current Liabilities 11.49b) / Total Assets 39.86b
(B) -0.36 = Retained Earnings (Balance) -14.24b / Total Assets 39.86b
(C) 0.07 = EBIT TTM 2.67b / Avg Total Assets 40.81b
(D) -0.51 = Book Value of Equity -16.66b / Total Liabilities 32.60b
Total Rating: -1.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 53.00

1. Piotroski 2.0pt
2. FCF Yield 1.78%
3. FCF Margin 5.47%
4. Debt/Equity 2.36
5. Debt/Ebitda 4.04
6. ROIC - WACC (= 0.87)%
7. RoE 11.08%
8. Rev. Trend 62.85%
9. EPS Trend -14.25%

What is the price of TEVA shares?

As of January 01, 2026, the stock is trading at USD 31.21 with a total of 4,941,880 shares traded.
Over the past week, the price has changed by -1.67%, over one month by +16.80%, over three months by +54.50% and over the past year by +41.61%.

Is TEVA a buy, sell or hold?

Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.
  • Strong Buy: 6
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the TEVA price?

Issuer Target Up/Down from current
Wallstreet Target Price 32.8 5%
Analysts Target Price 32.8 5%
ValueRay Target Price 40.6 30.2%

TEVA Fundamental Data Overview December 30, 2025

Market Cap USD = 36.59b (36.59b USD * 1.0 USD.USD)
P/E Trailing = 52.2787
P/E Forward = 11.2233
P/S = 2.1809
P/B = 5.0465
P/EG = 1.2934
Beta = 0.669
Revenue TTM = 16.78b USD
EBIT TTM = 2.67b USD
EBITDA TTM = 3.69b USD
Long Term Debt = 16.77b USD (from longTermDebt, last quarter)
Short Term Debt = 24.0m USD (from shortTermDebt, last quarter)
Debt = 17.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.89b USD (from netDebt column, last quarter)
Enterprise Value = 51.47b USD (36.59b + Debt 17.09b - CCE 2.20b)
Interest Coverage Ratio = 1.80 (Ebit TTM 2.67b / Interest Expense TTM 1.49b)
FCF Yield = 1.78% (FCF TTM 918.0m / Enterprise Value 51.47b)
FCF Margin = 5.47% (FCF TTM 918.0m / Revenue TTM 16.78b)
Net Margin = 4.24% (Net Income TTM 712.0m / Revenue TTM 16.78b)
Gross Margin = 50.09% ((Revenue TTM 16.78b - Cost of Revenue TTM 8.37b) / Revenue TTM)
Gross Margin QoQ = 51.43% (prev 50.34%)
Tobins Q-Ratio = 1.29 (Enterprise Value 51.47b / Total Assets 39.86b)
Interest Expense / Debt = 1.22% (Interest Expense 209.0m / Debt 17.09b)
Taxrate = 33.02% (214.0m / 648.0m)
NOPAT = 1.79b (EBIT 2.67b * (1 - 33.02%))
Current Ratio = 1.11 (Total Current Assets 12.74b / Total Current Liabilities 11.49b)
Debt / Equity = 2.36 (Debt 17.09b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 4.04 (Net Debt 14.89b / EBITDA 3.69b)
Debt / FCF = 16.22 (Net Debt 14.89b / FCF TTM 918.0m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 712.0m / Total Assets 39.86b)
RoE = 11.08% (Net Income TTM 712.0m / Total Stockholder Equity 6.43b)
RoCE = 11.53% (EBIT 2.67b / Capital Employed (Equity 6.43b + L.T.Debt 16.77b))
RoIC = 7.61% (NOPAT 1.79b / Invested Capital 23.54b)
WACC = 6.74% (E(36.59b)/V(53.68b) * Re(9.50%) + D(17.09b)/V(53.68b) * Rd(1.22%) * (1-Tc(0.33)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.18%
[DCF Debug] Terminal Value 76.85% ; FCFE base≈1.10b ; Y1≈1.35b ; Y5≈2.31b
Fair Price DCF = 26.38 (DCF Value 30.27b / Shares Outstanding 1.15b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -14.25 | EPS CAGR: 0.34% | SUE: 0.28 | # QB: 0
Revenue Correlation: 62.85 | Revenue CAGR: 2.39% | SUE: 0.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=-0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=2.79 | Chg30d=-0.040 | Revisions Net=-2 | Growth EPS=+5.5% | Growth Revenue=-0.1%

Additional Sources for TEVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle